Foresee Pharmaceuticals (TPEx: 6576) (“Foresee”) announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), that China’s National Medical Products Administration (NMPA) has approved the Marketing Authorization Application (MAA) for CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for the treatment of adult patients with advanced prostate cancer. GenSci will launch and commercialize the product in China under an exclusive license spanning all current and pipeline indications.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Marketing Authorization Application (MAA) approved |
| Product | CAMCEVI® 42 mg – sustained-release, ready-to-use 6-month subcutaneous formulation of leuprolide mesylate |
| Indication | Treatment of adult patients with advanced prostate cancer |
| Approval Date | Announced 12 Oct 2026 |
| Commercialization Partner | Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) – exclusive China license |
| Existing Approvals | United States (since May 2021), European Union (since May 2022), and other markets |
Product Profile & Mechanism of Action
- Molecule: Leuprolide mesylate, a gonadotropin-releasing hormone (GnRH) agonist — the hormonal backbone of androgen deprivation therapy (ADT) in advanced prostate cancer.
- Formulation: A sustained-release, ready-to-use, 6-month subcutaneous depot formulation, offering a less-frequent dosing alternative to existing therapies.
- Dosing Advantage: Half-yearly administration reduces injection frequency relative to 1- and 3-month leuprolide depots, supporting adherence in patients on long-term ADT.
- Ready-to-Use Design: The product requires no reconstitution or mixing at the point of care, simplifying administration.
- Global Regulatory Footprint: Approved for adult advanced prostate cancer in the United States (since May 2021), the European Union (since May 2022), and other markets — with China now added. Product labeling may differ by country per locally approved prescribing information.
Licensing Structure & China Commercialization
- Exclusive License: CAMCEVI® is exclusively licensed to GenSci for commercialization in China across all current and pipeline indications, including advanced prostate cancer, central precocious puberty (CPP), and premenopausal breast cancer.
- Launch Responsibility: GenSci will launch CAMCEVI® 42 mg in China, leveraging its domestic commercial infrastructure in endocrinology and oncology.
- Management Commentary: Dr. Ben Chien, PhD, Chairman and CEO of Foresee, stated: “We are pleased that our partner GenSci will be launching CAMCEVI® 42 mg in China. These efforts will significantly contribute to the growth of our global CAMCEVI® franchise.”
- Financial Terms: Not disclosed in the announcement.
Pipeline Expansion – Premenopausal Breast Cancer sNDA
| Item | Detail |
|---|---|
| Filing Type | Supplemental New Drug Application (sNDA) |
| Product | Leuprolide mesylate injectable emulsion |
| Additional Indication | Premenopausal breast cancer |
| Submission Date | May 2026 |
| Regulatory Status | Accepted by NMPA for substantive review |
Beyond the prostate cancer approval, GenSci submitted an sNDA in May 2026 for leuprolide mesylate injectable emulsion seeking the additional indication of premenopausal breast cancer — ovarian suppression in hormone-driven breast cancer being an established GnRH agonist use. The application has been accepted by the NMPA for substantive review; a decision timeline was not disclosed.
Disease & Treatment Context – Advanced Prostate Cancer ADT
- Standard of Care: Androgen deprivation therapy with GnRH agonists such as leuprolide remains the foundational systemic treatment for advanced prostate cancer, typically administered over years.
- Adherence Challenge: With 1- and 3-month formulations, patients face repeated clinic visits and injections; a 6-month depot addresses a recognized driver of dosing delays and non-adherence.
- China Market Access: Approval brings the half-yearly dosing option to China’s large prostate cancer population, where long-acting GnRH agonist depots are already established therapy.
Market Impact & Outlook
- Global Franchise Growth: The China approval extends CAMCEVI®’s commercial footprint across the US, EU, and China — the three largest pharmaceutical markets — contributing to what Foresee describes as growth of its global CAMCEVI® franchise through royalty and licensing economics.
- Multi-Indication Upside: The exclusive GenSci license covering prostate cancer, CPP, and premenopausal breast cancer positions the franchise for label expansion, with the breast cancer sNDA already under substantive NMPA review.
- Foresee’s Partnering Model: The milestone validates Foresee’s out-licensing strategy — retaining global economics while local partners execute market entry — for its sustained-release formulation platform.
- Competitive Landscape: CAMCEVI® competes in the long-acting GnRH agonist class, where 6-month leuprolide formulations remain a limited offering in China; pricing, reimbursement, and launch timing were not disclosed.
- Next Steps: GenSci’s China launch of CAMCEVI® 42 mg and NMPA review of the premenopausal breast cancer sNDA; timelines were not detailed.
Forward‑Looking Statements
This brief contains forward-looking statements, including statements regarding future plans for the commercialization of CAMCEVI® in China and the expected contribution of CAMCEVI® to the growth of Foresee’s global CAMCEVI® franchise. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.-Fineline Info & Tech
